Evidence map›Paper›PMID 42437162›Full record

ArticleKidney international reports2026

Kidney Survival in Children With Steroid-Resistant Nephrotic Syndrome Treated by Rituximab.

Eugene Yu-Hin Chan, Irene Yuk-Ying Ho, Chun-Ting Au, Ellen L M Yu, Andrea Angeletti, Sushmita Banerjee, Olivia Boyer, Chang-Yien Chan, Anna Francis, Gian Marco Ghiggeri and 22 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

Eugene Yu-Hin ChanDepartment of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR.
Irene Yuk-Ying HoDepartment of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR.
Chun-Ting AuDepartment of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR.
Ellen L M YuClinical Research Center, Princess Margaret Hospital, Hong Kong SAR.
Andrea AngelettiDivision of Nephrology, Dialysis, and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Sushmita BanerjeeCalcutta Medical Research Institute, Kolkata, India.
Olivia BoyerNéphrologie pédiatrique, centre de référence du syndrome néphrotique de l'enfant et de l'adulte, Hôpital Necker Enfants Malades, APHP, Institut Imagine, INSERM U1163, Université Paris Cité, Paris, France.
Chang-Yien ChanDepartment of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Anna FrancisDepartment of Nephrology, Queensland Children's Hospital, Brisbane, Australia.
Gian Marco GhiggeriDivision of Nephrology, Dialysis, and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Riku HamadaDepartment of Nephrology and Rheumatology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Nakysa HoomanAliasghar Clinical Research Development Center, Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Luke Sydney HopfDepartment of Pediatrics, University Medical Center Hamburg-Eppendorf, University Children's Hospital, Germany.
Mohamad Ikram IDepartment of Pediatrics, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kota Bharu, Kelantan, Malaysia.
Iftikhar IjazKing Edward Medical University, Lahore, Pakistan.
Dmytro D IvanovShupyk National Healthcare University of Ukraine, Kyiv, Ukraine.
Hee Gyung KangKidney Disease Center for Children and Adolescents, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea.
Laura LucchettiDivision of Nephrology, Bambino Gesù Children's Hospital, IRCCS Rome, Italy.
Francesca LuganiDivision of Nephrology, Dialysis, and Transplantation, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Alison Lap-Tak MaPaediatric Nephrology Centre, Hong Kong Children's Hospital, Hong Kong SAR.
William MorelloPediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.
Subal Kumar PradhanDivision of Pediatric Nephrology, SVPPGIP & SCB Medical College, Cuttack, India.
Larisa PrikhodinaVeltishev Research and Clinical Institute for Pediatrics and Children Surgery of Pirogov Russian National Research Medical University, Moscow, Russia.
Reem H RaafatPediatric Nephrology and Pediatric Kidney Transplant, Joe DiMaggio Children's Hospital, Memorial Health System, Hollywood, Florida, USA.
Rajiv SinhaPediatric Nephrology Unit, Institute of Child Health, Kolkata, India.
Sharon TeoDepartment of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Kouki TomariDepartment of General Pediatrics, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Okinawa, Japan.
Marina VivarelliLaboratory of Nephrology and Clinical Trial Center, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Hazel WebbDepartment of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK.
Hui Kim YapDepartment of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Desmond Yat-Hin YapDivision of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
Kjell TullusDepartment of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Kidney outcomes in children with steroid-resistant nephrotic syndrome (SRNS) following rituximab remain unclear. Methods: We conducted an international retrospective cohort study across 23 centers in 17 countries, including children with SRNS who did not respond to calcineurin inhibitors (CNIs) and subsequently, received rituximab. Patients with genetic variants were excluded. The primary outcome was kidney survival. Results: We analyzed data on 151 children (53% males; median age at onset: 6.8 years; primary vs. secondary SRNS: 54% vs. 46%; focal segmental glomerulosclerosis [FSGS]: 62%). All subjects received CNIs before rituximab (0-3 months: 21%; 3-6 months: 26%; 6-12 months: 26%; > 12 months: 26%). Upon rituximab, 73 subjects (48%) had normal kidney function, 47 (31%) had chronic kidney disease (CKD)2, and 31 (21%) had CKD3. Twenty-eight (19%) developed kidney failure. Overall kidney survival was 82.7%, 75.8%, and 72.3% at 3, 5, and 7 years post-rituximab. Baseline CKD staging before rituximab was associated with kidney survival at 5 years (log-rank Conclusion: Kidney survival of SRNS following add-on rituximab is 70% to 80% over 3 to 7 years. Nonresponse, preexisting CKD, lower albumin, and FSGS predict inferior kidney survivals.

Indexed as

childrenESKDnephrotic syndromepediatric nephrologyrituximabSRNS

Identifiers

PMID42437162
PMCPMC13355720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.